Comprehensive Review of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Monotherapy vs. Combination Therapy in CKD and Cardiovascular Disease
Introduction Sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as crucial pharmacological agents in managing type 2 diabetes, chronic kidney disease (CKD), and cardiovascular disease (CVD). These drug classes provide… Comprehensive Review of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Monotherapy vs. Combination Therapy in CKD and Cardiovascular Disease